Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder
Havva Nuket Isiten1,2, Merve Cebi2, Bernis Sutcubasi Kaya2
11 Department of Child and Adolescent Psychiatry, NPIstanbul Neuropsychiatry Hospital, Istanbul, Turkey.
Abstract:
EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies.
More Related Videos
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Mania and Antimanic Drugs: Overview
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Drug Therapy
Antianxiety Medications
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
